Related Experiment Video
Updated: Aug 18, 2026
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
[The heart in systemic lupus erythematosus. Study in 32 non-selected patients (author's transl)]
Insights
Systemic Lupus Erythematosus (SLE) can cause heart problems like pericarditis, myocarditis, and valvular disease. Early diagnosis and management of cardiac SLE are crucial for reducing patient morbidity and mortality.
Area of Science:
- Rheumatology and Cardiology
- Immunology and Cardiovascular Medicine
Context:
- Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations.
- Cardiovascular involvement is a significant cause of morbidity and mortality in SLE patients.
- Understanding the spectrum of cardiac manifestations is essential for timely intervention.
Purpose:
- To review and characterize the cardiovascular manifestations in a cohort of 32 patients with active SLE.
- To compare findings with existing literature and highlight potential underdiagnosis of certain cardiac conditions, such as valvular disease.
Summary:
- Pericarditis (22%), myocarditis (16%), and valvular disease (9%) were the primary cardiac manifestations observed.
- Secondary cardiac disease included heart failure, with or without hypertension.
- Valvular disease, though infrequently diagnosed during life, was noted in 9% of patients, suggesting it may be more prevalent than previously recognized in clinical settings.
Impact:
- This study emphasizes the importance of recognizing and managing cardiac SLE to improve patient outcomes.
- Findings suggest a need for increased vigilance regarding valvular disease in SLE patients.
- Improved diagnostic and management strategies for cardiac SLE can potentially reduce associated morbidity and mortality.
Abstract:
Cardiovascular manifestations of Systemic Lupus Erythematosus (SLE) in 32 unselected patients, with active disease were reviewed. Primary cardiac disease manifested as pericarditis (22%), myocarditis (16%), and valvular disease (9%), was recognized along with secondary disease as heart failure with or without systemic hypertension. Comparison with previous work by others, suggest that our cases are more representative of actual clinical picture of cardiac SLE. It is interesting to notice tht 9% of our patients had valvular disease, and this alteration is only occasionally found in other Hospitals. Valvular disease is rarely noticed during life, although is highly prevalent in autopsy series. We stress the diagnosis and management of the cardiac manifestations of SLE, in order to lower the morbidity and mortality of this condition.
